HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health, Beauty And Wellness Regulatory News: FDA, Kratom Group Trade Criticisms, LifeLink 'Key Words' Warned

This article was originally published in The Rose Sheet

Executive Summary

FDA's latest concern about kratom is "disturbingly high levels of heavy metals," but American Kratom Association adds to its reasons for "strong objections to methodology and lack of scientific rigor" in agency's finding that kratom is unsafe because some constituent ingredients are opioids. LifeLink supplement marketer caught FDA's attention not only for drug claims but also for key words on websites to identify diseases as search terms to find its products.


Related Content

Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules
Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations
Kratom Advocates Urge Industry Compliance, FDA And DEA Compassion





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts